Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

Status unconfirmed · Phase 2

Conditions studied: Aging

In brief

Assessing the effects of Quercitin and Dasatinib over a 16 week period on participatns' epigenetic biological aging. The patients are being tested at baseline, halfway point, and after the trial period.

Key facts

Study ID

NCT04946383

Run by

TruDiagnostic

People needed

25

Starts

2020-12-16

Expected to finish

2022-06-30

Last updated by the study team

2021-08-03

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men and women
• Ages 40 and older
• Patient must be able to comply with treatment plan and laboratory tests

You may not qualify if…

• Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
• No immune system issues or immunodeficiency disease
• No history of viral illness which could be reactivated by immune down regulation
• Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke)
• Diagnosis of a transient ischemic attack in the 6 months prior to screening
• Patients infected with hepatitis, C or HIV
• Patients with Body Mass Index (BMI) > 40 kg/m2
• Presence of active infection 9. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study
• Unable or unwilling to provide required blood sample for testing
• As for the male-participants they are recommended to avoid fertilization for the first 6 months after the clinical trial.
• If the patient has previously used Quercetin and Dasatinib.

Where it is running

• The Institute for Hormonal Balance — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.